Employers Tighten Requirements for Weight-Loss Drug Coverage
A growing number of US employers are imposing stricter requirements before covering GLP-1 weight-loss drugs, including mandatory weigh-ins, app tracking, and health coaching, while some are eliminating coverage entirely.
The landscape for GLP-1 weight-loss drug coverage is shifting as more US employers tighten prior authorization requirements, according to a report by The Wall Street Journal.
Details
The report indicates that many companies now require employees to undergo periodic weigh-ins, use diet and activity tracking apps, and participate in health coaching programs before approving coverage for drugs like Ozempic and Wegovy. In some cases, employers are choosing to drop coverage for these medications altogether.
Context
These changes come amid rising costs of GLP-1 drugs, which can exceed $1,000 per month per patient. Employers are seeking to curb escalating healthcare expenses, especially as demand for these drugs surges. Meanwhile, pharmaceutical companies such as Eli Lilly (ticker: LLY) and Novo Nordisk face pressure to maintain market share amid tightening coverage policies.
What It Means for Investors
These policies could impact adoption rates of GLP-1 drugs and, consequently, revenues for manufacturers. Investors should monitor coverage policy changes from major employers, as they may affect future demand for these medications.
Frequently Asked Questions
Found this useful? Share it